Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Phylogica
Phylogica
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Phylogica signs deal with UK biotech to identify and develop cancer drugs
Takes a 7.5% stake in PhoreMost, based in Cambridge
Research & Development
Phylogica enters into research and licensing agreement with Genentech
Perth, Australia-based company will receive an upfront payment of US$500,000
Research & Development
Phylogica expands peptide drug conjugates pact with Janssen
Australian firm has received an undisclosed payment to fund additional research
Research & Development
Phylogica enters peptide agreement with Janssen Biotech
To identify cell-penetrating Phylomer peptides
Research & Development
Phylogica forms target discovery spin-off
Sets up new venture called Phenomica with University of Cambridge in the UK
Research & Development
Phylogica completes first stage of collaboration with Roche
Receives undisclosed milestone payment
Research & Development
Phylogica to collaborate with Pfizer
To discover novel peptide-based vaccines
Subscribe now